Sildenafil citrate as oral solid lipid nanoparticles: A novel formula with higher bioavailability and sustained action for treatment of erectile dysfunction

Expert Opinion on Drug Delivery

Volumn 11, Issue 7, 2014, Pages 1015-1022

  Hosny, Khaled M ^a,b   Aljaeid, Bader M ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Beni Suef University   (Egypt)

Author keywords

Erectile dysfunction; Gelucire 44 14; Precirol ATO5; Sildenafil citrate; Solid lipid nanoparticles

Indexed keywords

GELUCIRE; GLYCEROL PALMITOSTEARATE; LIPID; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; SILDENAFIL; SOLID LIPID NANOPARTICLE; SURFACTANT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; ERECTILE DYSFUNCTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; RABBIT; SUSTAINED DRUG RELEASE; TABLET FORMULATION; THERMODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRASOUND; ZETA POTENTIAL;

ERECTILE DYSFUNCTION; GELUCIRE 44/14; PRECIROL ATO5; SILDENAFIL CITRATE; SOLID LIPID NANOPARTICLES;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG STABILITY; ERECTILE DYSFUNCTION; HALF-LIFE; LIPIDS; MALE; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RABBITS; SOLUBILITY; SULFONES;

EID: 84903136558     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.912212     Document Type: Article

References (43)

1. Jung Y, Seo G, Kim G, et al. Comparison of the solubility and pharmacokinetics of Sildenafil citrate salts. Arch Pharm Res 2011;34(3):451-4
2. Webb J, Freestone S, Allen J, et al. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999;83:21-8
3. Shin S, Bae K, Lee G. Pharmacokinetics of Sildenafil citrate after intravenous and oral administration in rats: Hepatic and intestinal first-pass effects Int J Pharm 2006;320:64-70
4. Fraisse A, Butrous G, Taylor M, et al Intravenous Sildenafil citrate for postoperative pulmonary hypertension in children with congenital heart disease Intensive Care Med 2011;37(3):502-9
5. Wang Y, Chow S, Zuo Z. Mechanistic analysis of pH-dependent solubility and trans-membrane permeability of Amphoteric compounds: Application to Sildenafil citrate Int J Pharm 2008;352:217-24
6. Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 2011;8(11):1407-24
7. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb) 2005;85:415-20 (Pubitemid 41617396
8. Münster U, Nakamura C, Haberland A, et al. RU 58841-Myristate- prodrug development for topical treatment of acne and Androgenetic Alopecia. Pharmazie 2005;60(1):8-12
9. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56(9):1257-72 (Pubitemid 38510473
10. Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for Tobramycin Int J Pharm 2002;238:241-5 (Pubitemid 34457892
11. Sznitowska M, Gajewska M, Janicki S, et al. Bioavailability of Diazepam from aqueous-organic solution, Submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm 2001;52(2):159-63 (Pubitemid 32755894
12. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug Incorporation and physicochemical characterization. J Microencapsul 1999;16(2):205-13 (Pubitemid 29099602
13. Dingler A, Gohla S. Production of solid lipid nanoparticles (SLN): Scaling up feasibilities. J Microencapsul 2002;19(1):11-16 (Pubitemid 34083457
14. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-96 (Pubitemid 32324113
15. Luo Y, Chen D, Ren L, et al. Solid lipid nanoparticles for enhancing Vinpocetine's oral bioavailability. J Control Release 2006;114(1):53-9 (Pubitemid 44144503
16. Zhang N, Ping Q, Huang G, et al. Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin Int J Pharm 2006;327:153-9 (Pubitemid 44667334
17. G€oppert TM, Müller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting Int J Pharm 2005;302:172-86 (Pubitemid 41242762
18. Kamble S, Vaidya K, Bhosale V, et al. Solid lipid nanoparticles and nanostructured lipid carriers-An overview Int J Pharma chemical Biolog Sci 2012;2(4):681-91
19. Ekambaram P, Sathali H, Priyanka K. Solid lipid nanoparticles: A review. Sci Rev Chem Commun 2012;2(1):82-5
20. Sinha VR, Srivastava S, Goel H, et al. Solid lipid nanoparticles (SLN's)- Trends and implications in Drug targeting Int J Adv Pharm Sci 2010;1:212-38
21. Cortesi R, Esposito E, Luca G, et al. Production of Lipospheres as carriers for bioactive compounds. Biomaterials 2002;23(11):2283-94 (Pubitemid 34234829
22. Song C, Liu S. A new healthy sunscreen system for human: Solid lipid nannoparticles as carrier for 3,4,5-Trimethoxybenzoylchitin and the improvement by adding Vitamin E Int J Biol Macromol 2005;36:116-19
23. Ahlin P, Kristl J, Smid-Kobar J. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in Dispersions. Acta Pharmaceutica 1998;48:257-67
24. Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of Valdecoxib. Drug Dev Ind Pharm 2006;32:911-18 (Pubitemid 44359752
25. Chen CC, Tsai TH, Huang ZR, et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010;74:474-82
26. Elshafeey A, Bendas E, Mohamed O Intranasal microemulsion of sildenafil citrate: In vitro evaluation and in vivo pharmacokinetic study in rabbits. AAPS PharmSciTech 2009;10(2):361-7
27. Meyyanathan SN, Muralidharan S, Rajan S, et al. A simple sample preparation with HPLC-UV method for estimation of amlodipine from plasma: Application to bioequivalence study. Open Chem Biomed Meth J 2008;1:22-7
28. Yang Z, Gao S, Wang J, et al. Enhancement of oral bioavailability of 20 (S)-ginsenoside Rh2 through improved understanding of its absorptionand efflux mechanisms. Drug Metab Dispos 2011;39:1866-72
29. Battaglia L, Trotta M, Gallarate M, et al. Solid lipid nanoparticles formed by solvent-in-water emulsion-diffusion technique: Development and influence on insulin stability. J Microencapsul 2007;24:672-84 (Pubitemid 47343461
30. Sanna V, Caria G, Mariani A. Effect of lipid nanoparticles containing fatty alcohols having different chain length on the ex vivo skin permeability of econazole nitrate. Powder Technol 2010;201:32-6
31. Shah KA, Date AA, Joshi MD, et al. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery Int J Pharm 2007;345:163-71 (Pubitemid 350087549
32. Tanvir S, Qiao L. Surface tension of nanofluid-Type fuels containing suspended nanomaterials. Nanoscale Res Lett 2012;7:226
33. Uner M, Wissing SA, Yener G, et al Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie 2004;59:331-2 (Pubitemid 38480731
34. Westesen K, Siekmann B, Koch MHJ Investigations on the physical state of lipid nanoparticles by synchrotron X-ray diffraction Int J Pharm 1993;93:189-99 (Pubitemid 23181296
35. Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?. Eur J Pharm Sci 2012;47:139-51
36. Yassin AE, Anwar MK, Mowafy HA, et al. Optimization of 5-fluorouracil solid-lipid nanoparticles: A preliminary study to treat colon cancer Int J Med Sci 2010;7:398-408
37. Liu J, Gong T, Wang C, et al. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholinebased mixed micelles: Preparation and characterization Int J Pharm 2007;340:153-62 (Pubitemid 47044961
38. Yang Q, Owusu-Ababio G. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm 2000;26:61-70 (Pubitemid 30075303
39. Surajit D, Wai K, Parijat K, et al. Formulation Design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: Effects of process variables. Colloids Surf B Biointerfaces 2011;88:483-9
40. Yosra E, Magda E, Ossama A. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles Int J Nanomedicine 2011;6:3195-205
41. Chen B, Yang Z, Lu L, Zhang Q In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull 2001;49(11):1444-7
42. Doijad C, Marvi V, Deshmukh V. Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles Int J Pharm 2008;70:203-7
43. Araujo L, Sheppard M, L?obenberg R, et al. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: Modification of the body distribution after suspension in surfactant solutions and in oil vehicles Int J Pharm 1999;176:209-24 (Pubitemid 29048305